perfluorotributylamine has been researched along with Osteosarcoma in 1 studies
*Osteosarcoma: A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed) [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, H; Chen, Y; Feng, K; Fu, Y; Huang, H; Mao, Y; Tian, H; Wang, J; Wang, W; Wang, X; Xu, Y; Zhang, Z; Zhou, Y | 1 |
1 other study(ies) available for perfluorotributylamine and Osteosarcoma
| Article | Year |
|---|---|
Polydopamine-coated UiO-66 nanoparticles loaded with perfluorotributylamine/tirapazamine for hypoxia-activated osteosarcoma therapy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Fluorocarbons; Humans; Indoles; Male; Metal-Organic Frameworks; Mice; Mice, Nude; Nanoparticles; Osteosarcoma; Phthalic Acids; Polymers; Tirapazamine; Tumor Hypoxia | 2021 |